Vaccine Adjuvants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Vaccine Adjuvants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

The global vaccine adjuvants market size reached US$ 773.6 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,617.3 Million by 2027, exhibiting a growth rate (CAGR) of 12.82% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Vaccines contain weakened and dead germs that initiate the immune response and activate antigen presenting cells (APCs). This reaction helps the body increase its ability to induce long-term protection and safety against any infection. Vaccine adjuvants are compounds that improve this immunogenic reaction of the body against antigens that have insufficient immunostimulatory capabilities. Aluminum salts and MF59, an oil-in-water emulsion composed of squalene, are among the two common adjuvants that are feasible for human use.

Vaccine Adjuvants Market Trends:
The global vaccine adjuvants market is primarily driven by the rising prevalence of allergies and infectious diseases, including cancer, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV) and tuberculosis. The need for advanced treatment options for existing and emerging fatal diseases has resulted in the development of vaccines that have long-lasting effects on immunization. For instance, key manufacturers have developed new adjuvants such as AS01, ISCOM & ISCOMMATRIX, and AS02, which are under clinical trials. Besides this, governments of various countries are taking initiatives for immunization and advancements in adjuvants for human use. They are also focusing on improving healthcare infrastructure and increasing investments for research and development (R&D) of new therapeutics. For example, market players are investing in the development of novel vaccine adjuvants as a potential solution against diseases caused by challenging pathogens, such as malaria and herpes, as well as for vulnerable populations that respond poorly to traditional vaccines, including older adults, neonates, and individuals with compromised immunity and comorbidities. Moreover, with the spread of the coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, there has been an increasing demand for effective and safe vaccine adjuvants. These factors are expected to provide a positive outlook for the market in the upcoming years.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine adjuvants market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, route of administration, diseases and application.

Breakup by Product Type:

Adjuvant Emulsions
Pathogen Components
Particulate Adjuvants
Combination Adjuvants
Others

Breakup by Route of Administration:

Oral
Intramuscular
Intranasal
Subcutaneous
Intradermal
Others

Breakup by Diseases:

Cancer
Infectious Diseases
Others

Breakup by Application:

Research
Commercial

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adjuvance Tecchnologies Inc., Adjuvatis, Agenus Inc., Brenntag SE, Chemtrade Logistics Inc., CSL Limited, Croda International Plc, Invivogen, Novavax Inc., OZ Biosciences and Virometix AG.

Key Questions Answered in This Report:
How has the global vaccine adjuvants market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global vaccine adjuvants market?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the diseases?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global vaccine adjuvants market and who are the key players?
What is the degree of competition in the industry?